RBR-9wwstd
Active, not recruiting
未知
se of 18FDG-PET-CT as a predictor of efficacy for locoregional control and survival in the treatment of Head and Neck Squamous-Cell Carcinoma
AC Camargo Cancer Center0 sitesNovember 24, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Scamous Cell- Carcinoma of Head and NeckNeoplasmsPositron Emission Tomography Computed Tomography
- Sponsor
- AC Camargo Cancer Center
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with locally advanced squamous cell carcinoma of the head and neck; Clinical Stages III, IVa and IVb;
- •Patients with primary tumors of oral cavity, oropharynx, larynx and hypopharynx;
- •Patients candidates for curative therapy with induction chemotherapy with the use of 03 drugs (taxanes, platinum and fluoropyrimidine) followed by radiotherapy associated with chemotherapy;
Exclusion Criteria
- •Heart disease active or not compensated by treatment, or acute myocardial infarction in the previous 6 months.
- •Active infection present (at the discretion of the investigator); Concomitant systemic diseases considered serious by the investigator; Another primary neoplasm (except in situ carcinoma of the uterine cervix or adequately treated basal cell carcinoma of the skin); Presence of severe psychiatric illness;
- •Participation in another experimental drug protocol;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis.bone metastasisJPRN-UMIN000005866ational Cancer Center Research Projects Management expenses Grants from the Government to National Cancer Research Center220
Not yet recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after anti-PD-1 antibody in patients with previously treated advanced non-small cell lung cancer: a multi-institutional studyPreviously treated advanced non-small cell lung cancerJPRN-UMIN000031009Gunma University120
Recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancerPreviously treated advanced non-small cell lung cancerJPRN-UMIN000020814Gunma30
Unknown
Not Applicable
sefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung canceradvanced non-small cell lung cancerJPRN-UMIN000026730Gunma University Hospital50
Completed
Not Applicable
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165